ArticleBritish journal of cancer2017
In-depth proteomic analysis of tissue interstitial fluid for hepatocellular carcinoma serum biomarker discovery.
Article in British journal of cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 50 citations in OpenAlex.
- Prognostic value of SPARC in hepatocellular carcinoma: A systematic review and meta-analysis.PloS one · 2022Pooled it
- Diagnostic and Prognostic Roles of Thrombospondin-2 in Digestive System Cancers.BioMed research international · 2022Pooled it
- Article
- Review
- A lactate-α-ketoglutarate metabolic circuit in tumor-infiltrating regulatory T cells accelerates tumor progression by inducing NK cell senescence.Nature cancer · 2026Article
- Plasma proteomic profiling reveals distinct protein signatures associated with hepatocellular carcinoma in chronic hepatitis B infection.Clinical proteomics · 2026Article
- Thrombospondin 2 as a Predictive Biomarker for HCC in Hepatitis C Patients: A Longitudinal Study Following DAA Therapy.Journal of viral hepatitis · 2025Article
- Application of Intelligent Medical Sensing Technology.Biosensors · 2023Review
- Epidermal Wearable Biosensors for the Continuous Monitoring of Biomarkers of Chronic Disease in Interstitial Fluid.Micromachines · 2023Review
- Identification of potential modifier genes in Chinese patients with Wilson disease.Metallomics : integrated biometal science · 2022Article
- Thrombospondin-2 as a diagnostic biomarker for distal cholangiocarcinoma and pancreatic ductal adenocarcinoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Article
- Beyond liquid biopsy: Toward non-invasive assays for distanced cancer diagnostics in pandemics.Biosensors & bioelectronics · 2022Review
- End-to-end design of wearable sensors.Nature reviews. Materials · 2022Review
- Review
- SPARC Overexpression Promotes Liver Cancer Cell Proliferation and Tumor Growth.Frontiers in molecular biosciences · 2021Article
- Quantitative proteomics identifies a plasma multi-protein model for detection of hepatocellular carcinoma.Scientific reports · 2020Article
- Minimally Invasive Biospecimen Collection for Exposome Research in Children's Health.Current environmental health reports · 2020Review
- Low Levels of SPARC are Associated with Tumor Progression and Poor Prognosis in Human Endometrial Carcinoma.OncoTargets and therapy · 2020Article
- New Blood Biomarkers for the Diagnosis of AFP-Negative Hepatocellular Carcinoma.Frontiers in oncology · 2020Review
- HKR3 regulates cell cycle through the inhibition of hTERT in hepatocellular carcinoma cell lines.Journal of Cancer · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatocellular carcinoma (HCC) is a primary malignancy of the liver. New serum biomarkers for HCC screening are needed, especially for alpha-fetoprotein (AFP) negative patients. As a proximal fluid between body fluids and intracellular fluid, tissue interstitial fluid (TIF) is a suitable source for serum biomarker discovery.
methodsSixteen paired TIF samples from HCC tumour and adjacent non-tumour tissues were analysed by isobaric tags for relative and absolute quantitation (iTRAQ) method. Two proteins were selected for ELISA validation in serum samples.
resultsTotally, 3629 proteins were identified and 3357 proteins were quantified in TIF samples. Among them, 232 proteins were significantly upregulated in HCC-TIF and 257 proteins down-regulated. Two overexpressed extracellular matrix proteins, SPARC and thrombospondin-2 (THBS2) were selected for further validation. ELISA result showed that the serum levels of SPARC and THBS2 in HCC patients were both significantly higher than those in healthy controls. The combination of serum SPARC and THBS2 could distinguish HCC (AUC=0.97, sensitivity=86%, specificity=100%) or AFP-negative HCC (AUC=0.95, sensitivity=91%, specificity=93%) from healthy controls. And the combination of serum SPARC and THBS2 could also distinguish HCC patients from benign liver disease patients (AUC=0.93, sensitivity=80%, specificity=94%). In addition, serum THBS2 was found to be a novel independent indicator for poor prognosis of HCC.
conclusionsNovel HCC candidate serum markers were found through in-depth proteomic analysis of TIF, which demonstrated the successful utility of TIF in cancer serum biomarker discovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.